

Global Corporate Overview



Better Health, Brighter Future

Last Updated April 2024

Important notice



For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("**Takeda**") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Comm

Medical information

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. "At Takeda, patients always come first. We also believe that a focus on trust, reputation, and business, in that order, sets us apart"

> Christophe Weber President & CEO

SUPPORTING PATIENTS FOR 242 YEARS



Who we are

Creating better health for people and a brighter future for the world is Takeda's purpose. The science and technology we advance are constantly evolving, but through our enduring values our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while creating an exceptional experience for our people.



Our Corporate Philosophy





Purpose	Better health for people, brighter future for the world.				
Vision	Discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.				
Values: Takeda-ism	We are guided by our values of Takeda-ism which incorporate Integrity, Fairness, Honesty and Perseverance, with Integrity at the core. They are brought to life through actions based on Patient-Trust-Reputation-Business, in that order.				
Imperatives					
PATIENT		PEC	PLE	PLANET	
 Responsibly translate science into highly innovative, life-transfor medicines and vaccine 			eate an exceptional ople experience	• Protect our planet	

UNLEASH THE POWER OF DATA AND DIGITAL

• We strive to transform Takeda into the most trusted, data-driven, outcomes-based biopharmaceutical company

A global biopharmaceutical company



Takeda Executive Team







President,

US Business Unit

CHRISTOPHE WEBER Representative Director; President & CEO AKIKO AMAKAWA Corporate Strategy Officer, CEO Chief of Staff ANDY PLUMP Director; President,

Research & Development

ASUKA MIYABASHIRA President, Japan Pharma Business Unit ELAINE SHANNON Global Quality Officer GABRIELE RICCI Chief Data & Technology Officer **GILES PLATFORD** President, Plasma-Derived Therapies Business Unit

NATIONALITIES

AGES **30-60**s



Chief Human Resources

MARCELLO AGOSTI Global Business Development Officer

MILANO FURUTA Chief Financial Officer MWANA LUGOGO Chief Ethics & Compliance Officer •

RAMONA SEQUEIRA President, Global Portfolio Division

women **53%**



TAKAKO OHYABUTChief Global Corporate AffairsP& Sustainability OfficerC

TERESA BITETTI President, Global Oncology Business Unit THOMAS WOZNIEWSKI Global Manufacturing & Supply Officer **YOSHIHIRO NAKAGAWA** Global General Counsel

How we innovate

We are building one of the most exciting and diverse pipelines in the industry. We follow science and aim to unlock innovation wherever it originates - whether we are developing a therapy in one of our laboratories or through our more than 200 partnerships. Together with our investments in data and digital technologies, we aim to improve the patient experience and revolutionize our approach to science.



We aim to discover and deliver life-transforming treatments



GASTROINTESTINAL & PLASMA-DERIVED THERAPIES INFLAMMATION Immunodeficiencies Neuroimmunology Inflammatory Bowel disease (IBD) Hematology Celiac disease Pulmonology • Dermatological & Rheumatic diseases • Specialty & critical care Liver diseases • Other rare & chronic diseases Neurogastric disorders **ONCOLOGY RARE DISEASES** Solid tumors **Rare Hematology and Hemostasis** Hematology Hemophilia • Von Willebrand disease Thrombotic thrombocytopenic purpura **NEUROSCIENCE Rare Immunology** Hereditary Angioedema • Rare epilepsies Immune Deficiency diseases • Sleep-wake disorders Rare Autoimmune disorders Parkinson's disease Hypoalbuminemia & Hypovolemia Severe Congenital Protein C deficiency Prothrombin deficiency VACCINES¹ Alpha-1 Antitrypsin deficiency Rare Metabolic Dengue • Hunter syndrome • COVID-19 • Fabry disease • Zika Gaucher disease Pandemic influenza • CMV & transplant

Research and development




Approx. 30

NEW MOLECULAR ENTITY CLINICAL STAGE ASSETS

Robust Clinical Pipelines of Novel Mechanisms

Approx. **50%**

Of pipeline with orphan drug designation potential in at least one indication/ in any region.



Diversified Modalities in Research

Leveraging patient insights, matching the right target with the right modality and executing experiments with rigor to accelerate therapies with transformative potential.



Active Partnerships

More than 60% of our pipeline is partnered, allowing us to tap cutting-edge science and innovation at the source. External partnerships with startups, biotech and academia help us bring innovative solutions to patients.



R&D Investment for FY22

In addition to late-stage programs with potential to launch multiple treatments in the near-term, critical programs in earlier stages of development provide sustainable long-term opportunities to advance scientific innovation.

> *Amount as of June 30, 2023. FY22 based on exchange rate of 131 JPY to 1 USD.

Our approach to sustainability

Our sustained growth through enduring values fuses why we exist (our purpose) with where we are going (our vision) and how we deliver on our vision (our values).

By using our core strengths and capabilities as a biopharmaceutical company, Takeda creates long-term value for patients, stakeholders and society while also sustaining positive impact for our people, communities, and the planet.



Our Sustainability Framework



PATIENT	PEOPLE	PLANET
Deliver innovative life-transforming medicines and vaccines	Develop talent and invest in lifelong learning	Achieve net-zero ambition
Provide health benefits that are valued by patients and society	Advance diversity, equity and inclusion	Conserve natural resources
Accelerate global, equitable access to medicines and vaccines	Create a culture of well-being	Design with sustainability in mind

DATA, DIGITAL AND TECHNOLOGY ENABLES OUR INNOVATION

SUSTAINED BUSINESS GROWTH

Our efforts in data, digital and technology enable us to accelerate innovation and provide sustained positive impact



PATIENT

Deliver **personalized experiences for patients** and optimized therapeutic outcomes.

Improve data, enable easier patient access, and improve diversity within **clinical trials**.

Use **predictive analytics** (AI and Generative AI) to target future dengue outbreaks, support clinical trials and new drug development, and strengthen our supply chain.

PEOPLE


Upskill our workforce of the future to create a **culture of digital thinking** and efficient solutions.

Provide a consistent, intuitive, inclusive and collaborative **technology experience** wherever, whenever and however our people work. Pursue a GreenTech strategy through consolidating data centers, cloud efficiencies, recycling tech while sustainably procuring new devices.

Design a **sustainability data collection strategy** with digital efficiencies and automation.

Develop analytics and reporting on environmental impact.

PLANET



Access to Medicine (AtM) programs



Our AtM programs continue to positively impact the lives of patients, particularly those diagnosed with a serious condition in underserved communities around the world.





Health Systems Strengthening

We are working with diverse partners in low- and middleincome countries and countries with evolving healthcare systems to build capability in the health care system

Bridging the Affordability Gap



Takeda's Innovative Patient Affordability and Charitable Access Programs provide access to innovative medicines in more than **44 countries and territories** around the world. These programs have bridged the affordability gap for more than **5,000** patients.

Building Trust



In 2022, we ranked in the **top 10** out of the 20 largest pharmaceutical companies evaluated by the Access to Medicines Index (**7**th overall). <u>AtM-Index rankings</u>

Our passion for people transforms our work into meaningful action



We believe we can create an exceptional people experience for everyone at Takeda by focusing on these four areas:

- **Talent** | Develop and attract top talent to deliver our vision with a highly engaged workforce
- **Well-being** | Focus on empowering life-work alignment to enhance wellbeing and increase productivity.
- **Diversity, Equity & Inclusion** | Drive positive change by promoting and improving diversity, equity and inclusion
- **Learning** | Create an environment that fosters lifelong learning and a growth mindset, enabling employees to thrive inside and outside of Takeda



RECOGNITION AROUND THE WORLD

Proud to be recognized around the world for our workplace environment and employee offerings.







Excellence in

2023


Health & Well-being

OUR WAYS OF WORKING

We're evolving our ways of working to build a flexible, enriching experience that fosters our values, promotes employee well-being and creates inclusion with regular face-to-face interactions for specific work and collaboration.

Our actions to reduce our impact on the environment





working toward purchasing 100% renewable electricity, which will result in a 30% annual reduction of GHG emissions



Conversion will reduce operational greenhouse gas emissions by 40-50% in two locations



Annual reduction of electricity purchases by ca. 833 MWh and elimination of GHG emissions by approximately 280 metric tons



First positive energy building following the Singapore zero energy building scheme



Our actions to reduce our impact on the environment







Net-zero GHG emissions from our own operations before 2035

Net-zero GHG emissions across our value chain **before 2040**

60% Freshwater Consumption Reduced Lessines, Belgium

First large-scale wastewater recycling facility of its kind to be used in the pharmaceutical industry.



Waste-to-Landfill Diversion

In FY2022, more than 80% of our waste was diverted from landfills.



Supplier Collaboration Energize Program

A first-of-its-kind initiative by 19 pharma companies to increase access to renewable energy sources for suppliers



Sustainability by Design Lead to Industry-First Process

Applying "Green Chemistry" Principles to R&D process led to reducing water usage in the manufacturing process



Our Global CSR Program and partnerships



Our Global CSR Program strives for better health for people and a brighter future for the world, where prevention measures are exponentially advanced, the health workforce is empowered, systems are prepared against emergency shocks, and people are freed from the burden of disease, with reliable access to quality care.

GLOBAL CSR PROGRAM (FY2016-2023)



GLOBAL CSR PARTNERSHIPS

WORKING TOGETHER WITH GAME-CHANGING MULTILATERAL AND ACADEMIC INSTITUTIONS WORLDWIDE







Published: April 2024 Global Corporate Affairs





Appendix

Our history 1781 – 1979



1781

S

BUSINES

0 8

Ľ.

COMPANY FOUNDED

Chobei Takeda I sets up his business in Osaka

1895 PRODUCTION

Pharmaceutical manufacturing begins in Takeda's factory

1871

INTERNATIONAL TRADE Takeda pioneers in the importation of western medicines

1914

PROPRIETARY "NC RESEARCH which activities begin are e

1940

Manufacturing Plant"

OSAKA FACTORY

Opens as "Takeda

Pharmaceutical

1915

"NORI" PRINCIPLES which underpin Takeda-ism, are established

1943

COMPANY NAME

becomes "Takeda Pharmaceutical Company Limited"

1946 HIKARI FACTORY

Opens in Yamaguchi prefecture

Takeda listed on the stock market

INITIAL PUBLIC

1949

OFFERING

1950s

PANVITAN® & ALINAMIN®

Japan's first multivitamin product and a Vitamin B1 derivative launch

1951

INTERNATIONAL BUSINESS

Starts with North and Central America and Asia

1961 COMPANY LOGO

The current "Dakiyama" logo is created



林式會社式田長兵衛高店 店 主 武田長兵衛高店

シートンは、「「「「「「「」」」」







FOR SOCIETY

1933 TAKEDA GARDEN For Medicinal Plant Conservation opens

1960 SHOSHISHA FOUNDATION

1963 TAKEDA SCIENCE FOUNDATION

is established to support talented students who will contribute to society is established to encourage promising research and science technology

Our history 1980 – present



1980s & 90s

EXPANSION OF INTERNATIONAL BUSINESS

accelerates with the launch of leuprorelin, lansoprazole, candesartan, pioglitazone

2008

MILLENNIUM PHARMACEUTICALS

acquisition enhances innovation in oncology

2011

NYCOMED AQUISITION

expands Takeda's global footprint into more than 70 countries worldwide

2018

NEW YORK STOCK EXCHANGE LISTING

The only pharmaceutical company listed on both the TSE and the NYSE

SHONAN HEALTH INNOVATION PARK

opens as the first pharma-led open innovation ecosystem in Japan

TAKEDA GLOBAL HEADQUARTERS

opens in Tokyo, providing an environment that supports diverse workstyles

2019 SHIRE ACQUISITION

makes Takeda a global biopharmaceutical leader with a presence in approximately 80 countries



2009 Takeda joins the UNITED NATIONS GLOBAL COMPACT

2010 TAKEDA INITIATIVE

is formed to support the development of healthcare professionals in Africa

2016 ACCESS TO MEDICINES

program launched to improve access to care and treatment for patients in underserved communities

GLOBAL CSR PROGRAM

launched to contribute to the better health of people through disease prevention.

2019 TAKEDA INITIATIVE 2

launched to improve maternal and child health by integrating quality HIV, TB, and malaria services in Africa

S

BUSINES


ĸ

Р С

Corporate governance structure



Our advanced and robust corporate governance model has been, and will continue to be, critical to our success.



Board of directors – values and corporate governance



Takeda's Board of Directors is accountable for ensuring that all our decisions and actions are in the best interests of all stakeholders, and aligned with our values. 12 of our 15 Board members serve as Independent External Directors, bringing further diversity and global experience to the Board.

3 INTERNAL DIRECTORS



CHRISTOPHE WEBER Representative Director, President & CEO



COSTA SAROUKOS Director, Chief Financial Officer

12 INDEPENDENT EXTERNAL DIRECTORS



MASAMI IIJIMA External Director, Chair of the Board Meeting



OLIVIER BOHUON External Director



JEAN-LUC BUTEL External Director



IAN CLARK External Director



ANDY PLUMP Director, President, Research & Development



STEVEN GILLIS External Director



JOHN MARAGANORE External Director



MICHEL ORSINGER External Director



MIKI TSUSAKA External Director





KIMBERLY A. REED External Director



KOJI HATSUKAWA External Director, Chair of ASC



YOSHIAKI FUJIMORI External Director



EMIKO HIGASHI External Director